JP2010518082A5 - - Google Patents

Download PDF

Info

Publication number
JP2010518082A5
JP2010518082A5 JP2009549102A JP2009549102A JP2010518082A5 JP 2010518082 A5 JP2010518082 A5 JP 2010518082A5 JP 2009549102 A JP2009549102 A JP 2009549102A JP 2009549102 A JP2009549102 A JP 2009549102A JP 2010518082 A5 JP2010518082 A5 JP 2010518082A5
Authority
JP
Japan
Prior art keywords
alkyl
substituted
aryl
alkoxy
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009549102A
Other languages
English (en)
Japanese (ja)
Other versions
JP5425642B2 (ja
JP2010518082A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/001631 external-priority patent/WO2008115319A2/en
Publication of JP2010518082A publication Critical patent/JP2010518082A/ja
Publication of JP2010518082A5 publication Critical patent/JP2010518082A5/ja
Application granted granted Critical
Publication of JP5425642B2 publication Critical patent/JP5425642B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

JP2009549102A 2007-02-07 2008-02-07 合成ｔｌｒアゴニストの結合体およびそのための使用 Expired - Fee Related JP5425642B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88869907P 2007-02-07 2007-02-07
US60/888,699 2007-02-07
PCT/US2008/001631 WO2008115319A2 (en) 2007-02-07 2008-02-07 Conjugates of synthetic tlr agonists and uses therefor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013059721A Division JP2013127004A (ja) 2007-02-07 2013-03-22 合成ｔｌｒアゴニストの結合体およびそのための使用

Publications (3)

Publication Number Publication Date
JP2010518082A JP2010518082A (ja) 2010-05-27
JP2010518082A5 true JP2010518082A5 (enExample) 2011-03-31
JP5425642B2 JP5425642B2 (ja) 2014-02-26

Family

ID=39766655

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009549102A Expired - Fee Related JP5425642B2 (ja) 2007-02-07 2008-02-07 合成ｔｌｒアゴニストの結合体およびそのための使用
JP2013059721A Withdrawn JP2013127004A (ja) 2007-02-07 2013-03-22 合成ｔｌｒアゴニストの結合体およびそのための使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013059721A Withdrawn JP2013127004A (ja) 2007-02-07 2013-03-22 合成ｔｌｒアゴニストの結合体およびそのための使用

Country Status (17)

Country Link
US (3) US8357374B2 (enExample)
EP (2) EP2510946B1 (enExample)
JP (2) JP5425642B2 (enExample)
KR (1) KR20090109121A (enExample)
CN (1) CN101790380B (enExample)
AU (1) AU2008227128B2 (enExample)
CA (1) CA2677733A1 (enExample)
DK (1) DK2510946T3 (enExample)
EA (1) EA019151B1 (enExample)
ES (2) ES2456964T3 (enExample)
HU (1) HUE025555T2 (enExample)
IL (1) IL200240A (enExample)
PL (2) PL2510946T3 (enExample)
PT (1) PT2510946E (enExample)
SI (1) SI2510946T1 (enExample)
WO (1) WO2008115319A2 (enExample)
ZA (1) ZA200906094B (enExample)

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009504803A (ja) * 2005-08-22 2009-02-05 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｔｌｒアゴニスト
EP2029597A4 (en) 2006-05-31 2011-11-23 Univ California purine analogs
ES2456964T3 (es) 2007-02-07 2014-04-24 The Regents Of The University Of California Conjugados de agonistas de TLR sintéticos y usos de los mismos
WO2009049365A1 (en) * 2007-10-15 2009-04-23 Cooperative Research Centre For Asthma A method of prophylaxis and agents for use therein
JP2011511073A (ja) * 2008-02-07 2011-04-07 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｔｌｒ７活性化物質による膀胱の疾患の治療
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
WO2010093436A2 (en) 2009-02-11 2010-08-19 Carson Dennis A Toll-like receptor modulators and treatment of diseases
WO2010138192A2 (en) * 2009-05-27 2010-12-02 Selecta Biosciences, Inc. Nanocarriers possessing components with different rates of release
MX2012004706A (es) 2009-10-22 2012-06-08 Gilead Sciences Inc Derivados de purina o deazapurina utiles para el tratamiento de (inter alia) infecciones virales.
WO2011134668A1 (en) * 2010-04-30 2011-11-03 Telormedix Sa Phospholipid drug analogs
US9050319B2 (en) 2010-04-30 2015-06-09 Telormedix, Sa Phospholipid drug analogs
EP2563366A4 (en) * 2010-04-30 2013-11-20 Univ California USE OF PHOSPHOLIPID CONJUGATES FROM SYNTHETIC TLR7 AGONISTS
EP2563401A1 (en) * 2010-04-30 2013-03-06 Telormedix SA Methods for inducing an immune response
CN102905728B (zh) 2010-05-26 2015-11-25 西莱克塔生物科技公司 具有不偶合的佐剂的纳米载体组合物
WO2012038058A1 (en) 2010-09-21 2012-03-29 Telormedix Sa Treatment of conditions by toll-like receptor modulators
CN103517990A (zh) 2010-10-07 2014-01-15 通用医疗公司 癌症生物标志物
EP2640190A4 (en) 2010-11-05 2016-05-11 Selecta Biosciences Inc MODIFIED NICOTINIC COMPOUNDS AND ASSOCIATED METHODS
KR101946499B1 (ko) 2011-04-08 2019-02-11 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염 치료를 위한 피리미딘 유도체
CA2838023C (en) * 2011-06-03 2019-08-13 3M Innovative Properties Company Hydrazino 1h-imidazoquinolin-4-amines and conjugates made therefrom
EP2717919B1 (en) 2011-06-03 2016-08-03 3M Innovative Properties Company Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
US20130028857A1 (en) 2011-07-29 2013-01-31 Selecta Biosciences, Inc. Synthetic nanocarriers comprising polymers comprising multiple immunomodulatory agents
UA116083C2 (uk) 2011-11-09 2018-02-12 ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі Похідні пурину для лікування вірусних інфекцій
WO2013151771A1 (en) 2012-04-05 2013-10-10 Massachusetts Institute Of Technology Immunostimulatory compositions and methods of use thereof
PT2872515T (pt) * 2012-07-13 2016-07-27 Janssen Sciences Ireland Uc Purinas macrocíclicas para o tratamento de infeções virais
CN103566377A (zh) 2012-07-18 2014-02-12 上海博笛生物科技有限公司 癌症的靶向免疫治疗
WO2014052828A1 (en) 2012-09-27 2014-04-03 The Regents Of The University Of California Compositions and methods for modulating tlr4
EA035327B1 (ru) 2012-10-10 2020-05-28 Янссен Сайенсиз Айрлэнд Юси Производные пирроло[3,2-d]пиримидина для лечения вирусных инфекций и других заболеваний
CN111420045B (zh) * 2012-10-10 2023-03-31 深圳大学 免疫受体调节剂偶联体及其制备方法和应用、制备其的偶联前体以及合成偶联前体的化合物
ES2655843T3 (es) 2012-11-16 2018-02-21 Janssen Sciences Ireland Uc Derivados 2-aminoquinazolínicos sustituidos heterocíclicos para el tratamiento de infecciones víricas
MY191389A (en) 2013-02-21 2022-06-22 Janssen Sciences Ireland Uc 2-aminopyrimidine derivatives for the treatment of viral infections
CN105339346B (zh) * 2013-02-25 2017-03-08 斯克里普斯研究学院 Neoseptin：小分子佐剂
HK1220389A1 (zh) * 2013-03-14 2017-05-05 Wang Rongfu 调控调节性t细胞功能的方法和组合物
US20140328898A1 (en) * 2013-03-15 2014-11-06 Children's National Medical Center Nano-Liposomal Formulations and Methods of Use
CN105338983B (zh) * 2013-03-29 2019-10-25 爱尔兰詹森科学公司 用于治疗病毒感染的大环脱氮-嘌呤酮
JP6377139B2 (ja) 2013-05-24 2018-08-22 ヤンセン・サイエンシズ・アイルランド・ユーシー ウイルス感染症およびさらなる疾患の処置のためのピリドン誘導体
JP6763769B2 (ja) 2013-06-27 2020-09-30 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー ウイルス感染症および他の疾病の処置のためのピロロ［３，２−ｄ］ピリミジン誘導体
MX368625B (es) 2013-07-30 2019-10-08 Janssen Sciences Ireland Uc Derivados de tieno[3,2-d]pirimidinas para el tratamiento de infecciones virales.
US20160199499A1 (en) * 2013-08-16 2016-07-14 The Regents Of The University Of California Uses of phospholipid conjugates of synthetic tlr7 agonists
GB201321242D0 (en) 2013-12-02 2014-01-15 Immune Targeting Systems Its Ltd Immunogenic compound
GB201321737D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
EP3092255A4 (en) 2014-01-10 2017-09-20 Birdie Biopharmaceuticals Inc. Compounds and compositions for treating egfr expressing tumors
EP3760208B1 (en) 2014-06-25 2024-05-29 The General Hospital Corporation Targeting human satellite ii (hsatii)
CA2954446A1 (en) 2014-07-09 2016-01-14 Shanghai Birdie Biotech, Inc. Anti-pd-l1 combinations for treating tumors
EP3177601B1 (en) * 2014-08-06 2023-03-01 The Scripps Research Institute Tlr-independent small molecule adjuvants
MX386981B (es) * 2014-08-15 2025-03-19 Chia Tai Tianqing Pharmaceutical Group Co Ltd Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll 7 (tlr7).
CN112546238A (zh) 2014-09-01 2021-03-26 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
US10632151B2 (en) 2015-01-22 2020-04-28 University Of Massachusetts Cancer immunotherapy
WO2016191553A1 (en) * 2015-05-26 2016-12-01 Ohio State Innovation Foundation Nanoparticle based vaccine strategy against swine influenza virus
CA2990852A1 (en) 2015-06-26 2016-12-29 Beth Israel Deaconess Medical Center, Inc. Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells
CA2998995A1 (en) * 2015-09-29 2017-04-06 Astrazeneca Aktiebolag Adenine conjugate compounds and their use as vaccine adjuvants
CN105311032B (zh) * 2015-11-09 2018-09-25 深圳大学 Tlr7激动剂与酪氨酸激酶抑制剂联用在制备抗肿瘤药物中的应用
CN105315281B (zh) * 2015-11-16 2017-04-19 深圳大学 化合物i和化合物ii及其制备方法和应用
CN115554406A (zh) 2016-01-07 2023-01-03 博笛生物科技有限公司 用于治疗肿瘤的抗-cd20组合
CN106943598A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-her2组合
CN115252792A (zh) 2016-01-07 2022-11-01 博笛生物科技有限公司 用于治疗肿瘤的抗-egfr组合
IL263030B2 (en) 2016-05-16 2024-11-01 Access To Advanced Health Inst Pegylated liposomes and methods of use
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms
SG11201811448RA (en) 2016-07-01 2019-01-30 Janssen Sciences Ireland Unlimited Co Dihydropyranopyrimidines for the treatment of viral infections
US10300145B2 (en) 2016-07-15 2019-05-28 Massachusetts Institute Of Technology Synthetic nanoparticles for delivery of immunomodulatory compounds
KR102450287B1 (ko) 2016-09-29 2022-09-30 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염 및 추가적인 질환의 치료를 위한 피리미딘 프로드러그
WO2018077385A1 (en) * 2016-10-25 2018-05-03 Biontech Rna Pharmaceuticals Gmbh Dose determination for immunotherapeutic agents
CA3037046A1 (en) 2016-10-31 2018-05-03 University Of Massachusetts Targeting microrna-101-3p in cancer therapy
WO2018089688A1 (en) 2016-11-09 2018-05-17 Jinjun Shi Restoration of tumor suppression using mrna-based delivery system
EP3551034A1 (en) 2016-12-07 2019-10-16 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
CA3046019A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a tlr modulator
US11986480B2 (en) 2017-02-03 2024-05-21 Tohoku University Heterocyclic compound
CN118515666A (zh) 2017-04-27 2024-08-20 博笛生物科技有限公司 2-氨基-喹啉衍生物
KR20200019226A (ko) 2017-06-23 2020-02-21 버디 바이오파마슈티칼즈, 인크. 약학 조성물
US20200163880A1 (en) 2017-07-13 2020-05-28 Danmarks Tekniske Universitet Cationic liposomes
US10494370B2 (en) 2017-08-16 2019-12-03 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor
US10487084B2 (en) 2017-08-16 2019-11-26 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor
US10472361B2 (en) 2017-08-16 2019-11-12 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor
US10457681B2 (en) 2017-08-16 2019-10-29 Bristol_Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor
US10508115B2 (en) 2017-08-16 2019-12-17 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
US11814623B2 (en) 2018-01-30 2023-11-14 University Of Massachusetts Methods of treating a wound using epigenetic regulation
US20210213041A1 (en) 2018-02-06 2021-07-15 The General Hospital Corporation Repeat rna as biomarkers of tumor immune response
TW202415645A (zh) 2018-03-01 2024-04-16 愛爾蘭商健生科學愛爾蘭無限公司 ２，４－二胺基喹唑啉衍生物及其醫學用途
CN110317202B (zh) * 2018-03-30 2021-12-24 江苏恒瑞医药股份有限公司 氰基吡咯并杂芳基类衍生物、其制备方法及其在医药上的应用
CN108379591B (zh) 2018-04-03 2022-03-29 深圳大学 免疫激动剂靶向化合物的合成及其应用
WO2019196918A1 (zh) * 2018-04-13 2019-10-17 罗欣药业(上海)有限公司 五元杂环并嘧啶类化合物、药物组合物及用途
US20210371440A1 (en) * 2018-04-13 2021-12-02 Glaxosmithkline Biologicals Sa Tlr7 and / or tlr8 agonists
WO2019209811A1 (en) 2018-04-24 2019-10-31 Bristol-Myers Squibb Company Macrocyclic toll-like receptor 7 (tlr7) agonists
US11554120B2 (en) 2018-08-03 2023-01-17 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
WO2020041720A1 (en) 2018-08-24 2020-02-27 Codiak Biosciences, Inc. Extracellular vesicles targeting dendritic cells and uses thereof
MX2021006547A (es) * 2018-12-17 2021-08-11 Eisai R&D Man Co Ltd Formulacion que comprende liposomas.
EP3921432A1 (en) 2019-02-04 2021-12-15 Codiak BioSciences, Inc. Membrane protein scaffolds for exosome engineering
US20220152188A1 (en) * 2019-03-14 2022-05-19 The Regents Of The University Of California Tlr4-tlr7 ligand formulations as vaccine adjuvants
EP3941511A2 (en) 2019-03-20 2022-01-26 Massachusetts Institute of Technology Uses of amphiphiles in immune cell therapy and compositions therefor
US12502427B2 (en) 2019-03-21 2025-12-23 Lonza Sales Ag Extracellular vesicles for vaccine delivery
US12233356B2 (en) 2019-03-21 2025-02-25 Lonza Sales Ag Process for preparing extracellular vesicles
CA3133314A1 (en) 2019-03-21 2020-09-24 Codiak Biosciences, Inc. Extracellular vesicle conjugates and uses thereof
US20220251200A1 (en) 2019-07-03 2022-08-11 Codiak Biosciences, Inc. Extracellular vesicles targeting t cells and uses thereof
AU2020349613B2 (en) * 2019-09-19 2025-11-13 Danmarks Tekniske Universitet Immune stimulating micelle composition
JP2022549328A (ja) 2019-09-25 2022-11-24 コディアック バイオサイエンシーズ， インコーポレイテッド 細胞外小胞組成物
US11744874B2 (en) * 2019-12-20 2023-09-05 Nammi Therapeutics, Inc. Formulated and/or co-formulated liposome compositions containing toll-like receptor (“TLR”) agonist prodrugs useful in the treatment of cancer and methods thereof
US20230122249A1 (en) 2020-01-27 2023-04-20 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
EP4097105A1 (en) 2020-01-27 2022-12-07 Bristol-Myers Squibb Company 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists
JP2023512204A (ja) 2020-01-27 2023-03-24 ブリストル－マイヤーズ スクイブ カンパニー トール様受容体７（ＴＬＲ７）アゴニストとしての１Ｈ－ピラゾロ［４，３－ｄ］ピリミジン化合物
WO2021154661A1 (en) 2020-01-27 2021-08-05 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
US20230144824A1 (en) 2020-01-27 2023-05-11 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
KR20220132594A (ko) 2020-01-27 2022-09-30 브리스톨-마이어스 스큅 컴퍼니 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물
CN115151546A (zh) 2020-01-27 2022-10-04 百时美施贵宝公司 作为Toll样受体7(TLR7)激动剂的C3-取代的1H-吡唑并[4,3-d]嘧啶化合物
KR20220132593A (ko) 2020-01-27 2022-09-30 브리스톨-마이어스 스큅 컴퍼니 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물
JP2023512207A (ja) 2020-01-27 2023-03-24 ブリストル－マイヤーズ スクイブ カンパニー トール様受容体７（ＴＬＲ７）アゴニストとしての１Ｈ－ピラゾロ［４，３－ｄ］ピリミジン化合物
WO2021168274A1 (en) 2020-02-21 2021-08-26 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
US20230107927A1 (en) 2020-02-28 2023-04-06 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
US20230114434A1 (en) 2020-03-13 2023-04-13 Codiak Biosciences, Inc. Extracellular vesicles for treating neurological disorders
JP2023518414A (ja) 2020-03-20 2023-05-01 コディアック バイオサイエンシーズ， インコーポレイテッド 治療のための細胞外小胞
WO2021231942A1 (en) * 2020-05-15 2021-11-18 The Board Of Trustees Of The Leland Stanford Junior University Toll-like receptor (tlr) agonist nanoparticles and uses thereof
WO2021237100A1 (en) 2020-05-21 2021-11-25 Codiak Biosciences, Inc. Methods of targeting extracellular vesicles to lung
WO2021248133A1 (en) 2020-06-05 2021-12-09 Codiak Biosciences, Inc. Anti-transferrin extracellular vesicles
CN111892648B (zh) * 2020-06-08 2022-08-26 中国科学院上海药物研究所 偶联tlr7激动剂的新型冠状病毒多肽疫苗及其应用
AU2021300362A1 (en) 2020-07-01 2023-02-23 ARS Pharmaceuticals, Inc. Anti-ASGR1 antibody conjugates and uses thereof
US12616692B2 (en) 2020-07-02 2026-05-05 ViiV Healthcare Company; and Method of achieving HIV viral remission using long-acting antiretroviral agents
US20240241020A1 (en) 2020-09-23 2024-07-18 Lonza Sales Ag Process for preparing extracellular vesicles
US20240082389A1 (en) 2020-09-23 2024-03-14 Lonza Sales Ag Methods of producing extracellular vesicles
WO2022066883A1 (en) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Extracellular vesicles comprising kras antigens and uses thereof
AU2021363606A1 (en) * 2020-10-21 2023-06-01 Univerza V Ljubljani Conjugated tlr7 and nod2 agonists
WO2022200553A2 (en) 2021-03-25 2022-09-29 Danmarks Tekniske Universitet Immune stimulating nanoparticle composition
AU2021447099A1 (en) * 2021-05-27 2023-02-16 Cas Lamvac (Guangzhou) Biomedical Technology Co., Ltd. Method and kit for analyzing phenotype and function of CD303
CN118574618A (zh) * 2021-11-03 2024-08-30 艾德森特克斯治疗股份有限公司 药物偶联物及其制备与使用方法
CN116162088B (zh) * 2022-12-14 2025-03-11 江苏省农业科学院 一种Toll样受体7激动剂纳米颗粒及其制备方法与应用

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
CA1271477A (en) 1983-11-18 1990-07-10 John F. Gerster 1h-imidazo[4,5-c]quinolin-4-amines
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5736553A (en) 1988-12-15 1998-04-07 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo 4,5-C!quinolin-4-amine
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US5037986A (en) 1989-03-23 1991-08-06 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo[4,5-c]quinolin-4-amines
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
NZ232740A (en) 1989-04-20 1992-06-25 Riker Laboratories Inc Solution for parenteral administration comprising a 1h-imidazo(4,5-c) quinolin-4-amine derivative, an acid and a tonicity adjuster
CA2093132C (en) 1990-10-05 2002-02-26 John F. Gerster Process for the preparation of imidazo[4,5-c]quinolin-4-amines
US5175296A (en) 1991-03-01 1992-12-29 Minnesota Mining And Manufacturing Company Imidazo[4,5-c]quinolin-4-amines and processes for their preparation
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5648516A (en) 1994-07-20 1997-07-15 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5525606A (en) 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
DE19505168A1 (de) 1995-02-16 1996-08-22 Boehringer Mannheim Gmbh Spezifische Lipidkonjugate von Nucleosid-Diphosphonaten und deren Verwendung als Arzneimittel
US5624677A (en) 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US5693811A (en) 1996-06-21 1997-12-02 Minnesota Mining And Manufacturing Company Process for preparing tetrahdroimidazoquinolinamines
US5741908A (en) 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
DE19637209B4 (de) 1996-09-12 2006-12-14 Siemens Ag Verfahren zum Steuern des Antriebsstrangs eines Kraftfahrzeugs und integrierte Antriebsstrangsteuerung
DE69735292T2 (de) 1996-10-25 2006-10-19 Gilead Sciences, Inc., Foster City Gefaesszellen wachstumsfaktor (vegf) nukleinsäureligand-komplexe
HUP9904665A3 (en) 1996-10-25 2000-11-28 Minnesota Mining And Mfg Co Sa Immune response modifier compounds for treatment of th2 mediated and related diseases
JPH10298181A (ja) 1997-04-25 1998-11-10 Sumitomo Pharmaceut Co Ltd タイプ２ヘルパーｔ細胞選択的免疫応答抑制剤
CA2309350C (en) 1997-11-12 2007-04-03 Mitsubishi Chemical Corporation Purine derivatives and medicaments comprising the same as active ingredient
CA2311742C (en) 1997-11-28 2009-06-16 Sumitomo Pharmaceuticals Co., Ltd. 6-amino-9-benzyl-8-hydroxypurine derivatives
JP4189048B2 (ja) 1997-12-26 2008-12-03 大日本住友製薬株式会社 複素環化合物
US7001609B1 (en) 1998-10-02 2006-02-21 Regents Of The University Of Minnesota Mucosal originated drug delivery systems and animal applications
US6486168B1 (en) 1999-01-08 2002-11-26 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
US20020058674A1 (en) 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
NZ512628A (en) 1999-01-08 2004-03-26 3M Innovative Properties Co Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
EP1244679B1 (en) 1999-12-17 2006-11-15 Ariad Pharmaceuticals, Inc. Purine derivatives
DE60028253T2 (de) 1999-12-17 2007-03-08 Ariad Pharmaceuticals, Inc., Cambridge Neue purine
DE60118521T2 (de) 2000-01-07 2006-10-12 Universitaire Instelling Antwerpen Purin derivate, ihre herstellung und verwendung
US6733764B2 (en) 2000-06-14 2004-05-11 Alain Martin Immunostimulator anti-cancer compounds and methods for their use in the treatment of cancer
JP2004510961A (ja) 2000-09-15 2004-04-08 ビルコ・ビーブイビーエイ 疾患の処置のための薬物療法を最適化するシステムおよび方法
GB0023008D0 (en) 2000-09-20 2000-11-01 Glaxo Group Ltd Improvements in vaccination
WO2002030399A2 (en) 2000-10-11 2002-04-18 Johns Hopkins University Polymer controlled delivery of a therapeutic agent
US20020127224A1 (en) 2001-03-02 2002-09-12 James Chen Use of photoluminescent nanoparticles for photodynamic therapy
EP1767525A1 (en) 2001-04-09 2007-03-28 Novartis Vaccines and Diagnostics, Inc. Guanidino compounds as melanocortin-4 receptor (MC4-R) agonists
JP4331944B2 (ja) 2001-04-17 2009-09-16 大日本住友製薬株式会社 新規アデニン誘導体
EP1572067A4 (en) 2001-05-18 2009-05-13 Sirna Therapeutics Inc CONJUGATES AND COMPOSITIONS FOR CELLULAR RELEASE
JP4335000B2 (ja) 2001-06-29 2009-09-30 シーブイ・セラピューティクス・インコーポレイテッド Ａ２ｂアデノシン・レセプタ拮抗剤
EP1440072A4 (en) 2001-10-30 2005-02-02 Conforma Therapeutic Corp PURINE ANALOGS HAVING HSP90 INHIBITORY ACTIVITY
GB0206461D0 (en) 2002-03-19 2002-05-01 Glaxo Group Ltd Improvements in vaccination
US7427629B2 (en) 2002-08-15 2008-09-23 3M Innovative Properties Company Immunostimulatory compositions and methods of stimulating an immune response
KR101111085B1 (ko) 2002-09-27 2012-04-12 다이닛본 스미토모 세이야꾸 가부시끼가이샤 신규 아데닌 화합물 및 그 용도
JP2004137157A (ja) 2002-10-16 2004-05-13 Sumitomo Pharmaceut Co Ltd 新規アデニン誘導体を有効成分として含有する医薬
US20040202663A1 (en) 2003-01-28 2004-10-14 Shanghai Sunway Biotech Co., Ltd. Therapy for primary and metastatic cancers
US20040265351A1 (en) 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
WO2005016235A2 (en) * 2003-04-14 2005-02-24 The Regents Of The University Of California Combined use of impdh inhibitors with toll-like receptor agonists
US20050059613A1 (en) 2003-07-08 2005-03-17 Bahram Memarzadeh Compositions and methods for the enhanced uptake of therapeutic agents through the bladder epithelium
WO2005020892A2 (en) 2003-08-08 2005-03-10 Mitochroma Research, Inc. Pharmaceutical compositions and methods for metabolic modulation
ATE465742T1 (de) 2003-09-05 2010-05-15 Anadys Pharmaceuticals Inc Tlr7-liganden zur behandlung von hepatitis c
JP2005089334A (ja) 2003-09-12 2005-04-07 Sumitomo Pharmaceut Co Ltd ８−ヒドロキシアデニン化合物
NZ546611A (en) 2003-09-18 2010-02-26 Conforma Therapeutics Corp Novel heterocyclic compounds as HSP90-inhibitors
FR2863890B1 (fr) 2003-12-19 2006-03-24 Aventis Pasteur Composition immunostimulante
AU2005219413A1 (en) 2004-03-02 2005-09-15 Massachusetts Institute Of Technology Nanocell drug delivery system
US8012964B2 (en) 2004-03-26 2011-09-06 Dainippon Sumitomo Pharma Co., Ltd. 9-substituted 8-oxoadenine compound
EP1728792A4 (en) * 2004-03-26 2010-12-15 Dainippon Sumitomo Pharma Co 8-OXOADENINVERBINDUNG
CA2587676A1 (en) 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna
DK1819230T3 (da) 2004-12-07 2012-08-20 Univ Miami Erytrocytafledte mikropartikler som hæmostatiske midler til kontrol af hæmoragi og til behandling af blødningsforstyrrelser
CA2601542C (en) 2005-03-21 2012-09-18 Ferrer Internacional, S.A. Method for making 1-substituted 1h-imidazo[4,5-c]quinolin-4-amine compounds and intermediates therefor
US20070292418A1 (en) 2005-04-26 2007-12-20 Eisai Co., Ltd. Compositions and methods for immunotherapy
JP2009504803A (ja) * 2005-08-22 2009-02-05 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｔｌｒアゴニスト
US20090118263A1 (en) 2005-09-22 2009-05-07 Dainippon Sumitomo Pharma Co., Ltd. Novel Adenine Compound
US20090105212A1 (en) 2005-09-22 2009-04-23 Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan Novel adenine compound
CN101340931A (zh) 2005-09-27 2009-01-07 科利制药公司 使用连接寡核苷酸调节tlr介导的免疫应答
US20070100146A1 (en) 2005-11-03 2007-05-03 Trevor Dzwiniel Process for the preparation of imidazo[4,5-c]-quinolin-4-amines
EP2029597A4 (en) 2006-05-31 2011-11-23 Univ California purine analogs
PT2038290E (pt) 2006-07-07 2013-12-10 Gilead Sciences Inc Moduladores de receptor do tipo toll 7
CL2007002866A1 (es) 2006-10-04 2008-07-04 Pharmacopeia Inc Compuestos derivados de 6-sustituidos-2-(bencimidazolil) purina y purinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de enfermedades autoinmunes, enfermedad inflamatoria, enfermedad mediada por m
US7902187B2 (en) 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
ES2456964T3 (es) 2007-02-07 2014-04-24 The Regents Of The University Of California Conjugados de agonistas de TLR sintéticos y usos de los mismos
SI2170888T1 (sl) 2007-06-29 2015-10-30 Gilead Sciences, Inc. Purinski derivati in njihova uporaba kot modulatorjev receptorja tipa toll-7
WO2009052310A1 (en) 2007-10-16 2009-04-23 Cv Therapeutics, Inc A3 adenosine receptor antagonists
JP2011511073A (ja) 2008-02-07 2011-04-07 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｔｌｒ７活性化物質による膀胱の疾患の治療
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
WO2010093436A2 (en) 2009-02-11 2010-08-19 Carson Dennis A Toll-like receptor modulators and treatment of diseases
MX2012004706A (es) 2009-10-22 2012-06-08 Gilead Sciences Inc Derivados de purina o deazapurina utiles para el tratamiento de (inter alia) infecciones virales.
WO2011134668A1 (en) 2010-04-30 2011-11-03 Telormedix Sa Phospholipid drug analogs
EP2563366A4 (en) 2010-04-30 2013-11-20 Univ California USE OF PHOSPHOLIPID CONJUGATES FROM SYNTHETIC TLR7 AGONISTS
EP2563401A1 (en) 2010-04-30 2013-03-06 Telormedix SA Methods for inducing an immune response
MX343914B (es) 2010-09-01 2016-11-18 Glaxosmithkline Biologicals Sa Adsorcion de inmunopotenciadores en sales metalicas insolubles.
WO2012038058A1 (en) 2010-09-21 2012-03-29 Telormedix Sa Treatment of conditions by toll-like receptor modulators

Similar Documents

Publication Publication Date Title
Yang et al. Reduction-responsive codelivery system based on a metal–organic framework for eliciting potent cellular immune response
US11938177B2 (en) Peptide vaccine formulations and use thereof for inducing an immune response
JP6993649B2 (ja) 免疫賦活活性を有するオリゴヌクレオチド含有複合体及びその用途
CN101790380B (zh) 合成tlr激动剂的缀合物及其应用
JP2021104038A (ja) 細胞透過性ペプチド、カーゴ、及びｔｌｒペプチドアゴニストを含む新規複合体
US10799580B2 (en) Expression vector delivery system and use thereof for inducing an immune response
Nevagi et al. Self-assembly of trimethyl chitosan and poly (anionic amino acid)-peptide antigen conjugate to produce a potent self-adjuvanting nanovaccine delivery system
CN110743008A (zh) 基于纳米颗粒的组合物
CN104587464B (zh) 一种基于氢氧化铝纳米粒的疫苗载体
Xia et al. Functionalized multi-walled carbon nanotubes for targeting delivery of immunostimulatory CpG oligonucleotides against prostate cancer
CN115702005A (zh) 用于有效核酸递送的载体
CN112566672A (zh) 制造基于肽的疫苗的改进方法
JP2013510882A5 (enExample)
US20260007737A1 (en) Lipid polysaccharide amino acid nanoparticles and use thereof
Atashgah et al. Protective efficacy of a PcrV-based vaccine formulated with chitosan nanoparticles against Pseudomonas aeruginosa infection in burn and sepsis mouse models
Brohlin Polymeric Encapsulation of Vaccines for Enhanced Immunogenicity
JP2025541816A (ja) Ｋｌｅｂｓｉｅｌｌａ ｐｎｅｕｍｏｎｉａｅに対するワクチン
EP4472662A2 (en) Nanostructure-based vector system for bacterial and viral antigens
HK40049623A (en) Improved methods of manufacturing peptide-based vaccines
Nevagi Self-assembly of TMC and poly (anionic amino acid)-peptide antigen conjugate to produce a potent self-adjuvanting nanovaccine delivery system
Morris c12) United States Patent
BRPI0807196B1 (pt) Compostos 6-amino-8-hidróxipurin-9-ilbenzil substituídos, e, usos dos mesmos
HK1138767B (en) Conjugates of synthetic tlr agonists and uses therefor